The highest daily number of coronavirus-linked deaths nationwide since the epidemic hit Malaysia in Jan 2020 was 63 deaths on May 26, with Selangor reporting 24 deaths, the highest in the country.
Malaysia reported 1,046 Covid-19 deaths from May 1-28 this year.
Top 5 states:
Selangor - 328 deaths
Johor - 132 deaths
KL - 110 deaths
Sarawak - 98 deaths
Kelantan - 74 deaths
Cumulative Covid-19 deaths in Malaysia as of May 28 this year: 2,552
May 1-28, 2021: 1,046 deaths (41%)
Jan - Apr 2021: 1,035 deaths (40.6%)
The whole of 2020: 471 deaths (18.5%)
About one in 10 Covid-19 fatalities reported from May 1-28 this year were brought in dead (died before seeking medical treatment).
BID cases comprised 99 of 1,046 Covid-19 fatalities (9.5%) reported in that period.
10 BID cases were reported on May 22, the highest daily rate.
More than four in 10 people who died from Covid-19 from May 1-28 this year perished in the Klang Valley that reported 439 fatalities, or 42% of 1,046 nationwide deaths.
Selangor: 328 deaths
KL: 110 deaths
Putrajaya: 1 death
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Malaysia's current medicine shortage isn't like previous "minor" perennial drug shortages, when certain meds tend to run out towards end of the year because of low funding.
This time, the med shortage may be far more critical & extensive because of global supply disruptions. 🧵
Malaysia is a net pharmaceutical importer.
This makes us extremely vulnerable to global supply disruptions caused by Covid pandemic, worsened by China lockdowns in 2022, and the Russia-Ukraine war that disrupted global supply chains across goods (not just pharmaceuticals).
Malaysia's entire supply of finished pharmaceutical products is either:
a) Directly imported
b) Indirectly imported via import of active pharmaceutical ingredients [APIs] (the active component of a drug), plus pharmaceutical intermediates and excipients (other components)
Agreements disclosed in a second lawsuit involving MySJ Sdn Bhd -- board power struggle -- show that MySJ owns the MySejahtera app, IP rights, and platform, while Entomo owns software used to develop the app.
Aug 2021 share sale agreement states MySJ is negotiating to acquire a health care management services company and a digital health care platform services company.
Mudah Healthcare & AmanInsure named in meeting minutes.
Both located in same address next to Entomo/MySJ's office.
AmanInsure Sdn Bhd's site even has mock-ups of MySejahtera with Covid-19 insurance/ takaful button (which scared me initially because AmanInsure didn't call it "mock-ups", but called it "User Journey).
Govt claims MySejahtera app/ IP ownership, but a private company can do this.
How @codebluenews broke the MySejahtera controversy: 🧵
PAC tabled its 2nd Covid vaccine procurement report on March 24. My colleague @alifahzndn spotted it in the Order Paper.
(CodeBlue checks Parliament order papers and replies to spot any bills/ answers related to health).
At that time, PAC chair @wongkahwoh didn't issue a statement about the release of PAC's Covid vaccine procurement report (should be done for reports in future).
This Pharmaniaga statement -- which MOH's ICR denounced as having "misrepresented" facts and evidence -- failed to mention that the Yale study did NOT compare Sinovac vs Pfizer boosters and that two Sinovac doses showed no "detectable" neutralizing antibodies against Omicron.
A Pfizer booster did elicit "detectable" neutralization against Omicron for double-vax Sinovac recipients, but only increased protection to similar levels as 2 Pfizer jabs.
In other words, 2 Sinovac + 1 Pfizer = 2 Pfizer.
NOT that a Sinovac booster is better than Pfizer booster
Hence why one of the authors of the Yale-Dominican Republic study suggested that Sinovac recipients may need two boosters to protect against Omicron, instead of one.
Because 1 Pfizer booster + 2 Sinovac doses only raises protection to 2 mRNA doses.
It is extremely deceptive to give the impression that a Pfizer booster for Sinovac recipients is less effective against Omicron and to put up another completely unrelated study to imply that a Sinovac booster is better than a Pfizer booster for Sinovac recipients.
If you want to talk about a research study on Sinovac alone, then don't headline your statement on another completely unrelated study.
Btw no company in the life sciences puts down another company's products.